cGAS-STING pathway

Where the papers sit

20 papers from the last 6 months study cGAS-STING pathway directly · updated from PubMed 12 Oct 2026

• Nanoparticle STING Immunotherapy

  Metal- and photoresponsive nanoplatforms are being developed to activate STING in poorly inflamed tumors. Manganese, reactive oxygen species, pyroptosis and immunogenic cell death repeatedly support dendritic-cell activation and tumor control. Hydrogels, bacterial systems and whole-tumor vaccines extend this strategy beyond conventional nanoparticles. Vaccine and inflammatory-disease applications suggest broader immune engineering, but efficacy remains mainly preclinical.

  9 papers · 45%

• Therapeutic STING Modulation

  Therapeutic cGAS-STING modulation is being tested across cancer, autoimmune disease and tissue complications. Dual cGAS/HDAC inhibitors represent an inhibitory strategy, while gels and copper nanotherapies activate antitumor immunity through chemoimmunotherapy, cuproptosis or photothermal injury. CDK4/6 inhibition links tumor subtype to immune response, whereas diabetic retinopathy highlights pathway-driven retinal damage. The shared focus is disease-specific control of STING rather than one established treatment direction.

  5 papers · 25%

• Mitochondrial Inflammation and Disease

  Mitochondrial damage and metabolic stress are recurring targets for restraining cGAS-STING-linked inflammation. SIRT3-DsbA-L-TFAM and mitochondrial homeostasis approaches address steatohepatitis and age-related sarcopenia. Other work combines STING targeting with cholesterol-crystal removal or ferroptosis immunotherapy, using hypoxia-responsive hydrogen sulfide and mitophagy. The field is moving toward pairing mitochondrial repair with selective immune and metabolic intervention.

  4 papers · 20%

• Neuroinflammation and Brain Injury

  Microglial cGAS-STING inhibition is being explored to limit neuroinflammation and neurological injury. Monotropein and C-176 reduce pathway activity alongside interferon beta and IL-6 responses. Benefits include improved neurological deficits and fewer long-term hydrocephalus symptoms. The remaining question is whether these approaches can translate beyond experimental brain injury.

  2 papers · 10%